COMPASS THERAPEUTICS, INC.: 10-Q filed 2020-02-14
What COMPASS THERAPEUTICS, INC. reported in its quarterly report filed 2020-02-14 (fiscal Q3 2020): 14 published measures, 37 facts as tagged in accession 0001213900-20-003689.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-02-14
- Fiscal period
- fiscal Q3 2020
- Accession
- 0001213900-20-003689 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All COMPASS THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 1,144 | USD | |
| At 2019-03-31 | 4,866 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 103,280 | USD | |
| At 2019-03-31 | 75,455 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | -102,136 | USD | |
| At 2019-03-31 | -70,589 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 1,144 | USD | |
| At 2019-03-31 | 4,866 | USD | |
| At 2018-12-31 | 4,679 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | -11,682 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -31,547 | USD | 275 |
| 2018-10-01 to 2018-12-31 | -10,142 | USD | 92 |
| 2018-04-01 to 2018-12-31 | -27,172 | USD | 275 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | -24,707 | USD | 275 |
| 2018-04-01 to 2018-12-31 | -22,946 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-12-31 | 20,985 | USD | 275 |
| 2018-04-01 to 2018-12-31 | 27,625 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | -102,636 | USD | |
| At 2019-03-31 | -71,089 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | -10,238 | USD | 92 |
| 2019-04-01 to 2019-12-31 | -27,707 | USD | 275 |
| 2018-10-01 to 2018-12-31 | -9,267 | USD | 92 |
| 2018-04-01 to 2018-12-31 | -24,946 | USD | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 1,144 | USD | |
| At 2019-03-31 | 4,866 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 1,444 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 3,840 | USD | 275 |
| 2018-10-01 to 2018-12-31 | 875 | USD | 92 |
| 2018-04-01 to 2018-12-31 | 2,226 | USD | 275 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 103,280 | USD | |
| At 2019-03-31 | 75,455 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 5,000,000 | shares | |
| At 2019-03-31 | 5,000,000 | shares |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-10-01 to 2019-12-31 | 10,238 | USD | 92 |
| 2019-04-01 to 2019-12-31 | 27,707 | USD | 275 |
| 2018-10-01 to 2018-12-31 | 9,267 | USD | 92 |
| 2018-04-01 to 2018-12-31 | 24,946 | USD | 275 |
Inspect the source
- Entity
- COMPASS THERAPEUTICS, INC. / CIK 0001738021
- Captured
- 2026-09-21T17:25:31.387Z
- SEC response SHA-256
9e12579e6cc358373d81361bc3010028797ebc5f19754d98e9f8de6b08aa1269
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001738021.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))